JAZZ: Summary for Jazz Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 2:10am EST - Canadian Markets open in 7 hours and 20 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Jazz Pharmaceuticals, Inc. (JAZZ)

On Nov 24: 7.77 USD

0.69 (9.75%)

MORE ON JAZZ

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Jazz Pharmaceuticals, Inc. (NGM:JAZZ) Delayed quote data

After Hours: 7.81

0.04 (0.51%) as of 7:32pm EST on 11/24/09

Last Trade:	7.77 USD
Trade Time:	Nov 24
Change:	0.69 (9.75%)
Prev Close:	7.08
Open:	6.98
Bid:	7.77 x 100
Ask:	7.88 x 1000
1y Target Est:	9.00

Day's Range:	6.75 - 8.18
52wk Range:	0.52 - 11.88
Volume:	1,230,821
Avg Vol (3m):	1,422,690
Market Cap:	240.81M
P/E (ttm):	N/A
EPS (ttm):	-2.38
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add JAZZ to Portfolio

Download Data

HEADLINES

•	Tuesday Options Recap
	at Seeking Alpha (Tue 3:58pm)

•	JAZZ PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
	EDGAR Online (Mon, Nov 23)

•	5 Stocks That Laugh at Wall Street
	at Motley Fool (Fri, Nov 13)

•	JAZZ PHARMACEUTICALS INC Financials
	EDGAR Online Financials (Wed, Nov 11)

•	Jazz Pharmaceuticals to Present at Investor Conference
	PRNewswire (Tue, Nov 10)

•	JAZZ PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi
	EDGAR Online (Tue, Nov 10)

•	New Star Analyst Rankings for Jazz Pharmaceuticals, Inc.
	StarMine (Sun, Nov 8)

•	JAZZ PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Fri, Nov 6)

•	HEADLINE STOCKS-U.S. small/midcap stocks on the move on Nov 6
	at Reuters (Fri, Nov 6)

•	Jazz Pharma 3Q loss narrows on Xyrem sales
	AP (Fri, Nov 6)

•	Jazz Pharmaceuticals cuts Q3 loss, boosts revenue
	at bizjournals.com (Thu, Nov 5)

More Headlines for JAZZ...

ANALYST

EPS Est (next year) (Dec-09) :	-0.37
EPS Est (in 2 years) (Dec-10) :	0.26
Avg Rec (current)*:	3.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•